South San Francisco, California – September 26, 2018.  Sutro Biopharma, Inc., a clinical stage drug discovery, development and manufacturing company focused on leveraging its proprietary integrated cell-free protein synthesis platform, XpressCF+™, to create a broad...

SOUTH SAN FRANCISCO, Sept. 12, 2018 – Sutro Biopharma, Inc., has appointed Stephen Worsley as chief business officer and has named Linda Fitzpatrick to the newly-created post of chief people and communications officer. Mr. Worsley has over 25 years of biotechnology...

Expand Clinical Research on Patients with Progressive Disease SOUTH SAN FRANCISCO, August 13, 2018– Sutro Biopharma, Inc.,and The Leukemia & Lymphoma Society® , or LLS, are partnering to develop STRO-001, Sutro’s CD74-targeting antibody-drug conjugate, to treat...

Funds Novel Cancer Treatments, Early-Stage Programs & Platform-Technology Advancement A Boost for Next-Generation Protein Therapies SOUTH SAN FRANCISCO, July 26, 2018 – Sutro Biopharma, Inc., has secured $85.4 million in Series E financing to advance its...

Sutro’s Cell-free Protein Synthesis Technology is Paired With Merck’s Immunology & Cancer Expertise SOUTH SAN FRANCISCO, July 24, 2018 –Sutro Biopharma, Inc., has signed a collaboration and licensing agreement with Merck, known as MSD outside the United States and...

SOUTH SAN FRANCISCO, April 26, 2018 -- Sutro Biopharma, Inc. has begun dosing patients in its initial clinical trial of its  potential first-in-class antibody drug conjugate, or ADC, product candidate, STRO-001, targeting CD74, a protein highly expressed in B-cell...

- Phase 1 Trial Planned for Late 2018 - Company’s First Cell-Free Protein SynthesisDrug for Solid Tumors SOUTH SAN FRANCISCO, April 16, 2018 – Sutro Biopharma’s first antibody drug conjugate (ADC) to treat solid tumors was highly effective against ovarian cancer in...

Results Presented at ASH are a Promising Sign as Company Prepares for STRO-001 Phase 1 Trial SOUTH SAN FRANCISCO, December 12, 2017 -- Two studies presented yesterday at the American Society of Hematology’s annual meeting in Atlanta showed frequent expression of CD74,...

Receives Celgene Payment, Completes Production for Clinical Trials of Internally-Developed ADC SOUTH SAN FRANCISCO, Oct. 11, 2017 -- Sutro Biopharma has received a manufacturing milestone payment from Celgene and has completed production of STRO-001, its first...

Will Rapidly Advance Promising Drug Candidates to the Clinic   SOUTH SAN FRANCISCO, Aug. 10, 2017 – Sutro Biopharma today announced it is refocusing its 2014 immuno-oncology collaboration with Celgene on four programs that are advancing through preclinical...